EGFR and cancer: Currently, anti-EGFR antibodies or specific tyrosine kinase inhibitors are being used in combination with radiation and certain chemotherapy agents in clinical trials for various types of cancer, as inhibition of the EGFR-related signal transduction pathway enhances the cytotoxic effects of radiation or various chemotherapy agents (Wu et al., 1995; Dent et al., 1999; Bonner et al., 2000).